95 related articles for article (PubMed ID: 21329793)
1. Targeting the unfolded protein response in cancer therapy.
Backer MV; Backer JM; Chinnaiyan P
Methods Enzymol; 2011; 491():37-56. PubMed ID: 21329793
[TBL] [Abstract][Full Text] [Related]
2. Targeting the unfolded protein response in glioblastoma cells with the fusion protein EGF-SubA.
Prabhu A; Sarcar B; Kahali S; Shan Y; Chinnaiyan P
PLoS One; 2012; 7(12):e52265. PubMed ID: 23284962
[TBL] [Abstract][Full Text] [Related]
3. GRP78 signaling hub a receptor for targeted tumor therapy.
Sato M; Yao VJ; Arap W; Pasqualini R
Adv Genet; 2010; 69():97-114. PubMed ID: 20807604
[TBL] [Abstract][Full Text] [Related]
4. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics.
Gaddameedhi S; Chatterjee S
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S61-6. PubMed ID: 20009298
[TBL] [Abstract][Full Text] [Related]
5. Suppression of cytokine responses by indomethacin in podocytes: a mechanism through induction of unfolded protein response.
Okamura M; Takano Y; Hiramatsu N; Hayakawa K; Yao J; Paton AW; Paton JC; Kitamura M
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1495-503. PubMed ID: 18799549
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of epidermal growth factor receptor-signaling pathway by binding of GRP78/BiP to the receptor under glucose-starved stress conditions.
Cai B; Tomida A; Mikami K; Nagata K; Tsuruo T
J Cell Physiol; 1998 Nov; 177(2):282-8. PubMed ID: 9766525
[TBL] [Abstract][Full Text] [Related]
7. Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells.
Backer JM; Krivoshein AV; Hamby CV; Pizzonia J; Gilbert KS; Ray YS; Brand H; Paton AW; Paton JC; Backer MV
Neoplasia; 2009 Nov; 11(11):1165-73. PubMed ID: 19881952
[TBL] [Abstract][Full Text] [Related]
8. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
Arteaga CL; Hurd SD; Dugger TC; Winnier AR; Robertson JB
Cancer Res; 1994 Sep; 54(17):4703-9. PubMed ID: 8062268
[TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
11. GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy.
Firczuk M; Gabrysiak M; Barankiewicz J; Domagala A; Nowis D; Kujawa M; Jankowska-Steifer E; Wachowska M; Glodkowska-Mrowka E; Korsak B; Winiarska M; Golab J
Cell Death Dis; 2013 Jul; 4(7):e741. PubMed ID: 23887632
[TBL] [Abstract][Full Text] [Related]
12. Glucose-deprived HT-29 human colon carcinoma cells are sensitive to verrucosidin as a GRP78 down-regulator.
Park HR; Ryoo IJ; Choo SJ; Hwang JH; Kim JY; Cha MR; Shin-Ya K; Yoo ID
Toxicology; 2007 Jan; 229(3):253-61. PubMed ID: 17161515
[TBL] [Abstract][Full Text] [Related]
13. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
14. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development.
Dong D; Ni M; Li J; Xiong S; Ye W; Virrey JJ; Mao C; Ye R; Wang M; Pen L; Dubeau L; Groshen S; Hofman FM; Lee AS
Cancer Res; 2008 Jan; 68(2):498-505. PubMed ID: 18199545
[TBL] [Abstract][Full Text] [Related]
15. Targeting the endoplasmic reticulum-stress response as an anticancer strategy.
Healy SJ; Gorman AM; Mousavi-Shafaei P; Gupta S; Samali A
Eur J Pharmacol; 2009 Dec; 625(1-3):234-46. PubMed ID: 19835867
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78.
Ermakova SP; Kang BS; Choi BY; Choi HS; Schuster TF; Ma WY; Bode AM; Dong Z
Cancer Res; 2006 Sep; 66(18):9260-9. PubMed ID: 16982771
[TBL] [Abstract][Full Text] [Related]
17. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
18. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ligand-based targeting for the EGF system in cancer.
Yotsumoto F; Sanui A; Fukami T; Shirota K; Horiuchi S; Tsujioka H; Yoshizato T; Kuroki M; Miyamoto S
Anticancer Res; 2009 Nov; 29(11):4879-85. PubMed ID: 20032451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
